Biocon has set the price band for an initial public offering of its clinical research services arm, Syngene International, at Rs 240-250 a share. Syngene’s IPO shall open for subscription on July 27 and close on July 29.
Earlier in June, Syngene received the Foreign Investment Promotion Board (FIPB) approval for raising foreign investment in the company to 44 per cent from the earlier approved 10 per cent. The equity shares of Syngene are proposed to be listed on BSE and the National Stock Exchange (NSE).
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: